in the quarter fell shor= of expectations, leading to a 14 percent decrease in its share price the day after it released its Q2 fi=ancial results. Cepheid's drop also came in spite of a sharp increase =n its Q2 revenues, which were up 21 percent <http://www.genomeweb.com/clinical-genomics/cepheid-repor